Sau buys GSK 47.7: Pozen continues company shift as GSK sells rights to migrane drug
Pozen had partnered with GSK (NYSE: GSK) on Treximet, but Glaxo just sold those rights to Pernix Therapeutics Holdings. Similarly, Pozen had partnered with Astra Zeneca (NYSE: AZ) for Vimovo, though that partnership ended and Pozen instead licensed the ... ...
37 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home